Full Length ArticleInhibitory effects of ASP6537, a selective cyclooxygenase-1 inhibitor, on thrombosis and neointima formation in rats

- Selective COX-1 inhibitor ASP6537 has a more potent antiplatelet effect than aspirin.
- ASP6537 showed dose-dependent antithrombotic effect in an arterio-venous shunt model.
- ASP6537 reduced neointima formation in a rat balloon angioplasty model.

IntroductionPercutaneous coronary interventions (PCIs), such as balloon angioplasty and stent placement, are effective in the treatment of coronary artery disease. PCI has drawbacks, however, including acute thrombosis after the procedure and restenosis of the vascular lumen due to abnormal neointimal hyperplasia. ASP6537 is a selective COX-1 inhibitor that has been investigated as a possible candidate for clinical development as an antiplatelet agent. In the present study, we evaluated the in vivo antithrombotic effect of ASP6537 and its effect on neointima formation after balloon angioplasty.Material and methodsThe antithrombotic effect of ASP6537 was examined using an arteriovenous shunt thrombosis model in rats while the effect of ASP6537 on neointima formation was evaluated in a rat carotid arterial balloon angioplasty model.ResultsIn the thrombosis study, ASP6537 dose-dependently decreased the protein content of the thrombus, while no prolongation of template bleeding time was observed. In the neointima study, ASP6537 reduced neointima formation.ConclusionsASP6537 may be a promising agent for the prevention of acute thrombosis and restenosis after PCI in place of aspirin.